NGVTIngevity Corporation

$69.64+25% 1Y

$69.64

$46.2052 weeks$77.87

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range.

1 good, 1 to watch, 1 without data

What the price assumes~+2% a yearderived · Jun 30, 2026

Priced for ~2% a year FCF growth. Little growth is priced in even as revenue fell 13% a year over three years, potential value, or a value trap.

Vs its own P/E rangedearer than 87% of its own historyderived

Expensive vs its own history: P/E 46.4 vs a 21.1 median over 31 quarters (+120% vs median).

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 86% of the market

FCF yieldbetter than 67% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Ingevity Corporation trades at 46.4× earnings against 31.1× for the median Specialty Chemicals name, more expensive than its own group.

46.4

Trailing P/E · Specialty Chemicals median 31.1 · 1.49× the median: the market pays up for this one

Price / sales: 2.06
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 6.5%
Free cash flow yield · Specialty Chemicals median 4.8%
Growth the price implies: +2.2%
Growth the price implies · The price pays for +2.2% free cash flow growth a year for a decade; the business has delivered +8.9% a year over the last three.

Details›

NGVT has re-rated away from its own history, so multiplying the old multiple by today's earnings prices a full reversal, not the business
Method	Per share
What its own history would imply	not meaningful, 46.4× today against a 21.1× median
52-week range	$46.20 – $77.87
Today	$69.64

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.

Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.

Ranks #5 of 33 by RyuScore